| 摘要 |
Disclosed is the use of a 4-amino-3-[1H-benzimidazol-2-yl]-1H-quinolin-2-one derivative of formula I (such as 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one); wherein the substituents are defined herein, for the manufacture of a medicament for treating drug-resistant cancer. Also disclosed is the above use, wherein the medicament is adapted for coadministration with an anti-cancer drug selected from imatinib mesylate (Gleevec), BAY43-9006, Brostallicin, lenalidomide (Revimid), thalidomide (Thalomid), docetaxel (Taxotere), erlontinib (Tarceva), vatalinib (PTK-787), VEGF-trap, fenretidine, bortezomib, a general monoclonal antibody, bevacizumab (Avastin), pertuzumab and/or rituximab.
|
